By Metro US
Posted on
(Reuters) – The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.
Previously, the use of Veklury was limited to patients requiring hospitalization.
(Reporting by Leroy Leo in Bengaluru; editing by Diane Craft)
Orioles send former No. 1 pick Jackson Holliday back to minors after he hit .059 in 10 MLB games
Golden Knights have limited Stars’ scoring chances to take 2-0 series lead
Giannis Antetokounmpo ruled out, Khris Middleton to start for Bucks against Pacers in Game 3
Hunter Dickinson announces his return to KU; UCLA signs Tyler Bilodeau from portal
QB Penix hears from Cousins, Vick after landing with Falcons as NFL draft first-round surprise pick
A ban in Kansas on gender-affirming care also would bar advocacy for kids’ social transitions
South Dakota governor, a potential Trump running mate, writes in new book about killing her dog
140,000 people did their taxes with the free IRS direct file pilot. But program’s future is unclear
Commerce Department announces new restrictions on U.S. firearms exports
New leaders take on Haiti’s chaos as those living in fear demand swift solutions to gang violence
Orioles send former No. 1 pick Jackson Holliday back to minors after he hit .059 in 10 MLB games
Golden Knights have limited Stars’ scoring chances to take 2-0 series lead
Giannis Antetokounmpo ruled out, Khris Middleton to start for Bucks against Pacers in Game 3
Hunter Dickinson announces his return to KU; UCLA signs Tyler Bilodeau from portal
